Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently shed light on. Cramer highlighted some of the stock’s possible catalysts, as he commented: “All right, next up, controversial, it’s ...

In recent years, Pfizer has transformed itself for the better via strategic decisions. The company's pending monster acquisition of Seagen is yet another example. Pfizer isn't done improving its ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

At Pfizer, a global approach to supply chain is crucial, one of the company's senior vice presidents says. In the U.S. pharmaceutical sector, supply chain resiliency is not achieved through ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a ...

While other industries got reamed by the pandemic, it’s said that pharmaceutical giant Pfizer “won” by moving tens of billions of dollars worth of COVID-19 medicine—enough to still report ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in ...

Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.